bisbenzimidazole has been researched along with Lymphoma, Non-Hodgkin in 1 studies
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In these cells and in chronic lymphocytic leukemia cells obtained from patients, there was considerable intercell heterogeneity in apparent adduct levels." | 1.29 | Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells. ( Frank, AJ; Proctor, SJ; Tilby, MJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frank, AJ | 1 |
| Proctor, SJ | 1 |
| Tilby, MJ | 1 |
1 other study available for bisbenzimidazole and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells.
Topics: Antineoplastic Agents, Alkylating; Bisbenzimidazole; DNA Adducts; DNA, Neoplasm; Feasibility Studies | 1996 |